Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Aparicio

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimenCarlos Gómez-Martin, Antonio Sánchez, Antonio Irigoyen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.
Oncology|March 28, 2018
A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group StudyJorge Aparicio, Alfonso Sánchez-Muñoz, Josep Gumà, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
European Urology Oncology|November 11, 2023
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines OfficeJoost L Boormans, Richard Sylvester, Lynn Anson-Cartwright, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2024
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH studyAna María López Muñoz, Encarnación González Flores, Alberto Carral Maseda, et al.
The Oncologist|September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter TrialCarlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 studyCarlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group studyJorge Aparicio, Pablo Maroto, Xavier García del Muro, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimenCarlos Gómez-Martin, Antonio Sánchez, Antonio Irigoyen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.
Oncology|March 28, 2018
A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group StudyJorge Aparicio, Alfonso Sánchez-Muñoz, Josep Gumà, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
European Urology Oncology|November 11, 2023
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines OfficeJoost L Boormans, Richard Sylvester, Lynn Anson-Cartwright, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2024
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH studyAna María López Muñoz, Encarnación González Flores, Alberto Carral Maseda, et al.
The Oncologist|September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter TrialCarlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 studyCarlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group studyJorge Aparicio, Pablo Maroto, Xavier García del Muro, et al.
Pageof 10